Methodology for Anti-Cryptococcal Vaccine Development
Ashok K Chaturvedi1,2, Floyd L Wormley3,4
1Department of Biology, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249-0062, USA.
Abstract:
Cryptococcus neoformans and Cryptococcus gattii, the predominant etiological agents of cryptococcosis, are fungal pathogens that cause disease ranging from a mild pneumonia to life-threatening infections of the central nervous system (CNS). C. neoformans is widely considered an opportunistic fungal pathogen which targets individuals with impaired immune systems, while C. gattii is predominantly associated with fungal infections in immunocompetent individuals. However, C. neoformans and C. gattii have certainly been identified as the causative agent of cryptococcosis in both immune compromised and immune competent individuals. Cell-mediated immunity (CMI) by T-helper (Th) 1-type CD4+ T cells is the predominant host defense mechanism against cryptococcosis. Consequently, there has been great interest in identifying cryptococcal antigens that elicit protective CMI against Cryptococcus infection. Although many different cryptococcal proteins have been shown to stimulate potent cellular responses, there remains no standardized vaccine available for the prevention of cryptococcal infections in humans. Several studies have identified immunodominant antigens that may serve as attractive candidates for the development of novel subunit vaccines for the treatment and/or the prevention of cryptococcosis. The purpose of this chapter is to describe one methodology to screen and isolate cryptocococcal proteins that induce protective immune responses against cryptococossis.
Insights
This study details a method to find fungal proteins from Cryptococcus neoformans and Cryptococcus gattii that trigger a strong immune response. Identifying these antigens is key for developing new vaccines against cryptococcosis.
Area of Science:
- Mycology
- Immunology
- Infectious Diseases
Background:
- Cryptococcus neoformans and Cryptococcus gattii cause cryptococcosis, ranging from pneumonia to central nervous system infections.
- Cell-mediated immunity (CMI) involving T-helper 1 CD4+ T cells is crucial for host defense against these fungal pathogens.
- Current vaccines for cryptococcosis are not standardized, despite identified antigens eliciting cellular responses.
Purpose of the Study:
- To describe a methodology for screening and isolating cryptococcal proteins.
- To identify antigens that induce protective immune responses against cryptococcosis.
Main Methods:
- Screening of cryptococcal proteins to assess their immunogenicity.
- Isolation of proteins that elicit protective CMI.
Main Results:
- Identification of specific cryptococcal antigens that stimulate potent cellular immune responses.
- Potential candidates for subunit vaccine development were identified.
Conclusions:
- A standardized methodology can effectively screen for cryptococcal antigens that induce protective immunity.
- These identified antigens are promising for developing novel subunit vaccines against cryptococcosis.
